Oct. 14 (Fri.) ,2016 13:30-15:30

Annex Hall

Simultaneous Interpretation

Advanced Gene Therapy toward Commercialization

Clinical gene therapy has been revived after long-term stagnation in Western countries. For example, adeno-associated virus (AAV) vectors have been successfully used for gene therapy of Parkinson’s disease, AADC deficiency, Leber’s congenital amaurosis, and hemophilia B. Regarding cancer gene therapy, there has been increasing focus on oncolytic virotherapy and chimeric antigen receptor (CAR)-expressing T cell gene therapy. Especially, CD19-targeted CAR-T gene therapy has had surprising clinical efficacy against acute lymphoblastic leukemia. In addition, clinical application of genome editing technology is attracting the most attention recently.


Keiya Ozawa

Director, IMSUT Hospital / Director, Center for Gene & Cell Therapy (CGCT) /
Professor, Division of Genetic Therapeutics, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo (IMSUT) / Visiting Professor, Division of Immuno-Gene & Cell Therapy (Takara Bio)
Jichi Medical University

Gene Therapy for Child Neurological Diseases –Effects for AADC Deficiency-

Takanori Yamagata

Professor, Dept. of Pediatrics, Jichi Medical University

Michael Linden

VP Gene Therapy and Head Genetic Medicine Institute, Pfizer

Oncolytic viral therapy -changing the paradigm of cancer treatment

Robert H.I. Andtbacka

Associate Professor, Surgical Oncology Department of Surgery, University of Utah / Co-Director, Melanoma Program, Huntsman Cancer Institute

Enhancing the Power of Allogeneic CAR T-Cells by Gene Editing

André Choulika

President and Chief Executive Officer, Cellectis

Renova Therapeutics: Transformational Gene Therapies and Peptide Infusions for Chronic Diseases

Jack W. Reich

CEO and Co-Founder, Renova Therapeutics

Close Window